+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07708753

Randomized Phase III Trial Comparing SYS6043 to Investigators Choice Chemotherapy in Women with Platinum-Resistant Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Led by CSPC Megalith Biopharmaceutical Co.,Ltd. · Updated on 2026-09-23

460

Participants Needed

1

Research Sites

60 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of SYS6043 compared to chemotherapy chosen by investigators in women with platinum-resistant ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. This Phase III, randomized, open-label, multicenter study aims to enroll about 460 eligible participants. The study focuses on patients whose cancer has progressed despite previous platinum-based treatments. Participants will be assigned to receive either SYS6043 once on Day 1 of each treatment cycle or one of several chemotherapy options selected by the investigator, including liposomal doxorubicin, paclitaxel, or topotecan, given in specific schedules every 28 days. Treatment will continue until disease progression, unacceptable side effects, withdrawal, or study termination by the sponsor. Tumor assessments using CT or MRI scans will occur at screening and then every 6 weeks for 36 weeks, followed by every 12 weeks until disease progression or other study endpoints. During the study, participants will undergo regular tumor evaluations and safety monitoring, including radiological scans and laboratory tests. After stopping treatment, they will continue to be followed for survival every two months until death, loss to follow-up, withdrawal, or study completion. The primary outcomes are progression-free survival and overall survival, measured up to approximately 16 and 39 months respectively. Additional assessments include response rates, duration of response, disease control rate, antibody levels, and adverse events throughout the study duration.

CONDITIONS

Brief Title

A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Research Team

C

Clinical Trials Information Group officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here